MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Integrated Clinical Research Intern Program: Impact Upon Recruitment of Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention.

    L. Lemon, A. Faraday, J. Nevins, M. Nygard, M. Mcmahon (Cincinnati, USA)

    Objective: To discuss the development and benefit of an online internship program created to expand recruitment and retention within a PD cohort and introduce students…
  • 2024 International Congress

    Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment

    D. Kremens, R. Hauser, A. Formella, M. Joshi, M. Grall (Philadelphia, USA)

    Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…
  • 2024 International Congress

    Neuroprotective Effect of Isoquercitrin in Rotenone Induced Parkinson’s Disease-Like Motor and non-motor Symptoms in Zebrafish

    KHA. Aran (Moga, India)

    Objective: The objective of study is to find out the effect of isoquercitrin, a plant-derived chemical, against Parkinson-like symptoms induced by rotenone in zebrafish.. Background:…
  • 2024 International Congress

    Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease

    R. Gordon, K. Bhatt, N. Jayabalan, N. Birch, A. Lehn, B. Oronsky, S. Caroen, T. Reid (Brisbane, Australia)

    Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…
  • 2024 International Congress

    Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis

    R. Tang, R. Sun, S. Zhang, L. Chen (Shanghai, China)

    Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…
  • 2024 International Congress

    Comparing the Selected Device-Aided Therapy of Movement Disorder Specialist Team with Patient Selections

    A. de Leon, O. Phokeawvarangkul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: This study aims to compare the decision made by patients and physicians in selecting device-aided therapy (DAT) for advanced Parkinson’s disease (aPD) and to…
  • 2024 International Congress

    Indications of advanced therapies in Parkinson’s Disease: a retrospective study in a Belgian reference center

    B. Delsaut, V. Leclercq, S. Dethy (La Louvière, Belgium)

    Objective: The aim of our study is to assess whether our patients with Parkinson’s disease (PD) met recommended criteria to perform advanced therapy (AT) like…
  • 2024 International Congress

    Effects of GBA mutations in patients with Parkinson’s disease and Levodopa-carbidopa intestinal gel: a nation-wide longitudinal multicentre ‘real-world’ study.

    R. Cilia, F. Colucci, E. Cereda, V. Leta, M. Zibetti, M. Carecchio, S. Bonvegna, G. Calandra-Buonaura, R. Cerroni, R. de Micco, S. Tamburin, L. Magistrelli, F. Lena, M. Mascia, M. Picillo, G. Cossu, M. Marano, C. Leuzzi, C. Comi, A. Zampogna, C. Pellicano, S. Barca, V. Fioravanti, A. Pilotto, R. Zangaglia, M. Avenali, C. Sorbera, F. Di Biasio, F. Arienti, A. Nicoletti, C. Bagella, MC. Malaguti, A. Ranghetti, E. Caputo, D. Alimonti, E. Torre, GD. Oggioni, AE. Elia, N. Golfrè Andreasi, G. Devigili, B. Garavaglia, G. Imbalzano, T. Schirinzi, F. Cavallieri, A. Priori, M. Sessa, F. Tamma, M. Canesi, P. Solla, M. Zappia, A. Di Fonzo, L. Avanzino, A. Quartarone, EM. Valente, C. Pacchetti, A. Padovani, F. Valzania, A. Suppa, MT. Pellecchia, N. Modugno, M. Tinazzi, A. Tessitore, A. Stefani, P. Cortelli, IU. Isaias, A. Antonini, MC. Sensi, L. Lopiano, R. Eleopra (Milan, Italy)

    Objective: To investigate the safety and efficacy of LCIG in PD, focusing on the effects of GBA status. Background: Parkinson's disease carriers of GBA mutations/variants…
  • 2024 International Congress

    Peri-Electrode Edema after Deep Brain Stimulation Implantation – Case Report and Literature Review

    M. Marchiori, L. Packer, R. Pessoa, N. Martins, A. Schilling, M. Brunet (Brazil)

    Objective: To report a case of peri-electrode edema after Deep Brain Stimulation (DBS), and discuss its main aspects. Background: PD is a neurodegenerative condition, and…
  • 2024 International Congress

    Bright Light Therapy: A Novel Non-Pharmacological Approach to Parkinson’s Disease

    QK. Lv, YR. Sun, F. Wang, CF. Liu (Suzhou, China)

    Objective: To assess the effectiveness of Bright Light Therapy (BLT) in ameliorating symptoms and neuropathology in an α-synuclein preformed fibril (α-syn PFF) induced Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 82
  • 83
  • 84
  • 85
  • 86
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley